SIG
BBH icon

Stanford Investment Group’s VanEck Biotech ETF BBH Stock Holding History

Stanford Investment Group’s Portfolio BBH Stock Details BBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,138
Closed -$122K – 26
2016
Q4 		$122K Buy
1,138
+4
+0.4% +$435 0.06% 77
2016
Q3 		$131K Buy
1,134
+250
+28% +$28.5K 0.06% 79
2016
Q2 		$91K Sell
884
-795
-47% -$84.8K 0.05% 95
2016
Q1 		$174K Hold
1,679
– – 0.1% 58
2015
Q4 		$213K Buy
1,679
+4
+0.2% +$490 0.12% 53
2015
Q3 		$191K Hold
1,675
– – 0.14% 50
2015
Q2 		$226K Hold
1,675
– – 0.17% 45
2015
Q1 		$217K Hold
1,675
– – 0.17% 44
2014
Q4 		$193K Buy
+1,675
New +$189K 0.16% 49

Other funds holding BBH

AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
MCM
Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return
MLL
Moody Lynn & Lieberson Boston, Massachusetts $1.9B AUM 27.82% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
SFS
Strategic Financial Services Utica, New York $2.28B AUM 22.9% 1-Year Est. Return

Stanford Investment Group's BBH Position: Q1 2017 in Review

Stanford Investment Group sold out of VanEck Biotech ETF (BBH) in Q1 2017, closing a stake of 1,138 shares — an estimated $122K sold.

Stanford Investment Group first reported a position in BBH in Q4 2014 and held it in 9 quarters. The position peaked at $226K in Q2 2015. 79 funds tracked by Wall St. Rank hold BBH as of Q1 2017.

  • Stanford Investment Group reported no remaining VanEck Biotech ETF position as of Q1 2017 after selling out during the quarter.
  • Stanford Investment Group sold 1,138 VanEck Biotech ETF shares in Q1 2017, an estimated $122K.
  • Stanford Investment Group first reported a position in VanEck Biotech ETF in Q4 2014 and held it in 9 quarters.
  • Stanford Investment Group's VanEck Biotech ETF position peaked at $226K in Q2 2015.
  • 79 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2017.

Based on Stanford Investment Group's 13F filing for Q1 2017.